GlassScriptPhysician profile
Karen A Ostrowski
NPI 1558447649
$2,123.97
in general payments reported to CMS, 2019-2025
17 companies · $728 in 2025
The $728 reported for 2025 was more than what 79% of Adult Health (Nurse Practitioner) providers received nationally (typical 2025 total: $182).
See the full distribution for Adult Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $361 · 2022: $321 · 2023: $288 · 2024: $426 · 2025: $728.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,370 · Education: $72.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,369.80 |
| Education | $72.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $651.98 | 2021-2025 | |
| Sun Pharmaceutical Industries INC. | $307.42 | 2021-2025 | Odomzo, Blu-U, Ilumya |
| Leo Pharma INC. | $232.92 | 2021-2025 | Adbry, Spevigo, Anzupgo |
| Novartis Pharmaceuticals Corporation | $204.59 | 2021-2025 | |
| Lilly USA, LLC | $124.99 | 2021-2025 | Ebglyss, Taltz |
| Incyte Corporation | $97.97 | 2022-2024 | Opzelura |
| E.R. Squibb & Sons, L.L.C. | $90.54 | 2023-2024 | Sotyktu |
| Janssen Biotech, INC. | $78.10 | 2021-2022 | |
| Amgen INC. | $76.56 | 2024-2025 | Otezla, Otezla |
| Boehringer Ingelheim Pharmaceuticals, INC. | $75.01 | 2025 | Spevigo |
| Arcutis Biotherapeutics, INC. | $63.39 | 2024-2025 | Zoryve |
| Biofrontera INC. | $36.64 | 2021-2022 | |
| Pfizer INC. | $21.14 | 2023 | |
| Genzyme Corporation | $19.80 | 2022 | |
| Galderma Laboratories, L.P. | $14.59 | 2025 | Nemluvio |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Almirall LLC | $14.28 | 2024 | Klisyri |
| Mimedx Group, INC. | $14.05 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Karen Ostrowski listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.